Ten Year Survival Patterns in Primary Breast Cancers Compared to Hormone Receptor Antigen Detection by Monoclonal Antibodies
The prognostic significance of immunocytochemical methods for estrogen (ER) and progesterone (PgR) receptor analyses was studied in 257 patients with primary breast cancer followed up to ten years. H222 antibody was used for ER and JZB39 used for PgR. ER positive (>10 fmol/mg prot) tumors using ligand assays showed disease free interval (DFI) advantage for 3 years but none after three years. H222 positive tumors were associated with survival advantage throughout the ten year period (p=0.004). PgR (by ligand analysis) advantage was only seen in the first 3.5 years. JZB39 positive tumors showed significant survival advantage through the ten year period (p=0.04). Both ER and PgR correlated with nuclear grade and histologic grade. Within histologic graDe S ER positive DFI advantage was observed only among HG II lesions (p=0.04). While separation within lymph node groups was observed in the initial period in each category, only the 1–3 node positive subgroup had distinct advantage throughout the period of follow-up. The data indicate that semi-quantitative immunocytochemical ER and PgR analyses contributes to the separation of prognostic groups among specific subgroups of primary breast cancer.
KeywordsBreast Cancer Estrogen Receptor Progesterone Receptor Primary Breast Cancer Positive Tumor
Unable to display preview. Download preview PDF.
- 1).E.V. Jensen, G.E. Block, S. Smith, K. Kyser, E.R. De Sombre. Estrogen receptors and breast cancer response to adrenalectomy. Natl. Cancer Inst. Monog. 34:55–69, 1971.Google Scholar
- 4).J.C. Allegra, M.E. Lippman, R. Simon, E.B. Thompson, A. Barlock, L. Green, K.K. Huff, H.M.T. Do, S.C. Aitken, and R. Warren. Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treat. Reports 63:1271–1277, 1979.Google Scholar
- 6).J.M.M. Raemaekers, L.V.A.M. Beex, A.J.M. Koenders, G.F.F.M. Pieters, A.G.H. Smals, T.J. Benraad, P.W.C. Kloppenborg and The Breast Cancer Group. Disease-free interval anDe Strogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up. Breast Cancer Res. Treat. 6:123–130, 1985.CrossRefGoogle Scholar
- 9).K.S. Mc Carty Jr., L.S. Miller, E.B. Cox, J. Konrath, K.S. Mc Carty Sr. Estrogen receptor analysis. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch. Path. and Lab. Med. 109:716–721, 1985.Google Scholar
- 12).E.R. De Sombre, S.M. Thorpe, C. Rose, R.R. Blough, K.W. Andersen, B.B. Rasmussen, and W.F. King. Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res. 46:4256s–4264s, 1986.Google Scholar
- 13).B. Fisher, E.R. Fisher, C. Redmond, A. Brown, and Contributing NSABP Investigators. Tumor nuclear grade, estrogen receptor and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer. Breast Cancer Res. Treat 7: 147–160, 1986.PubMedCrossRefGoogle Scholar